LXRX
Lexicon Pharmaceuticals, Inc.
1.58
+
0.04
2.60%
12 x 1.57
17 x 1.60
bid
ask
15 @ 04:00 PM
1.62+0.04 (2.49%)
Bearish
14
Bullish
51
sentiment
1.53
day range
1.61
1.00
52 week range
3.58
Prev Close1.54
Open1.55
Low1.53
High1.61
Volume1.27M
Avg. Volume4.56M
Market Cap389.05M
Inst. Own82.13%
Beta1.27
Short Ratio6.39
Div & Yield0.00 /
EPS-0.80
P/E0.00
1yr Target5.33
50day MA2.26
200day MA1.69
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -0.2 | N/A | N/A | N/A |
2024-03-11 | 2023-12 | -0.23 | -0.2 | 0.03 | 13.04% |
2023-11-08 | 2023-09 | -0.22 | -0.21 | 0.01 | 4.55% |
2023-08-03 | 2023-06 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-05-02 | 2023-03 | -0.17 | -0.17 | N/A | N/A |
2023-03-02 | 2022-12 | -0.14 | -0.16 | -0.02 | -14.29% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-30 | Citigroup | Upgrade | Buy | Buy |
2023-05-29 | Needham | Upgrade | Hold | |
2023-03-06 | Jefferies | Upgrade | Hold | |
2022-11-21 | Citigroup | Upgrade | Buy | Buy |
2022-08-11 | Piper Sandler | Upgrade | Overweight | |
2022-06-30 | Citigroup | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-27 | ALEXANDER KRISTEN | Officer | 47.80K | Conversion of Exercise of derivative security |
2023-11-12 | AMOUYAL PHILIPPE J | Director | 240.33K | Purchase |
2024-03-12 | ARTAL INTERNATIONAL S.C.A. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-02-27 | COATS LONNEL | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
2024-02-27 | CRUM BRIAN T | General Counsel | 177.50K | Conversion of Exercise of derivative security |
2024-02-27 | GRANOWITZ CRAIG B. M.D., PH.D. | Officer | 47.63K | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Artal Group S.A. | 117.55M | 269.20M | 48.00% |
2023-06-29 | BVF Inc. | 20.00M | 45.79M | 8.16% |
2023-06-29 | FMR, LLC | 8.51M | 19.49M | 3.47% |
2023-06-29 | Vanguard Group Inc | 6.46M | 14.79M | 2.64% |
2023-06-29 | Blackrock Inc. | 6.38M | 14.61M | 2.60% |
2023-06-29 | JP Morgan Chase & Company | 2.93M | 6.71M | 1.20% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.70M | 8.48M | 1.51% |
2023-08-30 | Fidelity Growth Company Fund | 2.53M | 4.35M | 1.03% |
2023-08-30 | iShares Russell 2000 ETF | 2.15M | 3.69M | 0.88% |
2023-06-29 | JP Morgan Small Cap Value Fund | 1.43M | 3.27M | 0.58% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.42M | 3.25M | 0.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.09M | 1.87M | 0.44% |
Split
...
Split | Date |
---|---|
1 : 7 | 2015-05-21 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
$LXRX they may try to get in on the low end, as low as they can, so they can get back in before the news comes and then when it skyrockets they maximize their profit. If they can get in low, then they may try to swing in till tomorrow after positive news this will open with a nice hike tomorrow
-
-
The last reported price for shares $LXRX was 1.46. Currently, the 1st Resistance Point for this stock is 1.56, with a 2nd Resistance Point sitting at 1.66. Meanwhile, this companys stock has a 1st Support Level at 1.32 and a 2nd Support Level at 1.19. I think we are safe to receive good news today
-
-
-
-
3 Top Penny Stocks to Buy According To Insiders In October
pennystocks.com • -
Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug
proactiveinvestors.com • -
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
Penny Stocks To Buy? 4 To Watch With Big News Now
pennystocks.com • -
4 Penny Stocks To Buy In June According To Insiders
pennystocks.com • -
U.S. FDA approves Lexicon Pharma's heart failure drug
reuters.com • -
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
5 Penny Stocks To Buy For Under $5
pennystocks.com • -
Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
seekingalpha.com • -
7 Biotech Stocks With Key Catalysts for May
investorplace.com • -
Hot Penny Stocks To Buy Before 2022? 3 Premarket Stocks To Watch
pennystocks.com • -
Recap: Lexicon Pharmaceuticals Q3 Earnings
benzinga.com • -
6 Penny Stocks To Buy According To Analysts, Targets Up To 322%
pennystocks.com • -
Lexicon Pharmaceuticals: Q2 Earnings Insights
benzinga.com • -
LXRX Stock Price Increased 18.67%: Why It Happened
pulse2.com • -
Lexicon Pharmaceuticals Still A Very High-Risk/High-Reward Biopharma Name
seekingalpha.com • -
Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier
seekingalpha.com • -
3 Biotech Stocks That Jumped Last Week
fool.com • -
LXRX Stock Alert: Why Lexicon Pharmaceuticals Is Up 100%+ Today
investorplace.com • -
Is Lexicon Pharma a Stock to Buy After 90% Runup and FDA Nod?
247wallst.com • -
Lexicon Pharma Sold LXRX Stock to Weight Watchers' Turn-Around Billionaire
investorplace.com • -
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
globenewswire.com • -
Lexicon Announces Offering of Common Stock
globenewswire.com • -
LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday
investorplace.com • -
Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today
investorplace.com • -
Lexicon Pharmaceuticals: Q3 Earnings Insights
benzinga.com • -
Dan Bilzerian's Ignite International Brands Is Falling Apart (OTCMKTS:BILZF)
seekingalpha.com • -
Wondering how much your Social Security check will increase next year?
marketwatch.com • -
Up to 41% of "miscellaneous" denied Social Security benefits not being reviewed • financialducksinarow.com
financialducksinarow.com • -
August Inflation: What It Means For Social Security, TIPS And I Bonds
seekingalpha.com •